These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
694 related articles for article (PubMed ID: 24056116)
1. Characterization of the intestinal and hepatic uptake/efflux transport of the magnetic resonance imaging contrast agent gadolinium-ethoxylbenzyl-diethylenetriamine-pentaacetic acid. Jia J; Puls D; Oswald S; Jedlitschky G; Kühn JP; Weitschies W; Hosten N; Siegmund W; Keiser M Invest Radiol; 2014 Feb; 49(2):78-86. PubMed ID: 24056116 [TBL] [Abstract][Full Text] [Related]
2. Dynamic contrast-enhanced MRI of the liver in Mrp2-deficient rats using the hepatobiliary contrast agent Gd-EOB-DTPA. Saito S; Obata A; Kashiwagi Y; Abe K; Murase K Invest Radiol; 2013 Jul; 48(7):548-53. PubMed ID: 23442774 [TBL] [Abstract][Full Text] [Related]
3. Hepatic uptake of the magnetic resonance imaging contrast agent Gd-EOB-DTPA: role of human organic anion transporters. Leonhardt M; Keiser M; Oswald S; Kühn J; Jia J; Grube M; Kroemer HK; Siegmund W; Weitschies W Drug Metab Dispos; 2010 Jul; 38(7):1024-8. PubMed ID: 20406852 [TBL] [Abstract][Full Text] [Related]
4. Pharmacokinetics and imaging properties of Gd-EOB-DTPA in patients with hepatic and renal impairment. Gschwend S; Ebert W; Schultze-Mosgau M; Breuer J Invest Radiol; 2011 Sep; 46(9):556-66. PubMed ID: 21623212 [TBL] [Abstract][Full Text] [Related]
5. Gadolinium-ethoxybenzyl-DTPA, a new liver-specific magnetic resonance contrast agent. Kinetic and enhancement patterns in normal and cholestatic rats. Clément O; Mühler A; Vexler V; Berthezène Y; Brasch RC Invest Radiol; 1992 Aug; 27(8):612-9. PubMed ID: 1428739 [TBL] [Abstract][Full Text] [Related]
6. Primovist, Eovist: what to expect? Van Beers BE; Pastor CM; Hussain HK J Hepatol; 2012 Aug; 57(2):421-9. PubMed ID: 22504332 [TBL] [Abstract][Full Text] [Related]
7. Dynamic contrast-enhanced magnetic resonance imaging of abdominal solid organ and major vessel: comparison of enhancement effect between Gd-EOB-DTPA and Gd-DTPA. Tamada T; Ito K; Sone T; Yamamoto A; Yoshida K; Kakuba K; Tanimoto D; Higashi H; Yamashita T J Magn Reson Imaging; 2009 Mar; 29(3):636-40. PubMed ID: 19243060 [TBL] [Abstract][Full Text] [Related]
8. Hepatic kinetics and magnetic resonance imaging of gadolinium-EOB-DTPA in dogs. Benness G; Khangure M; Morris I; Warwick A; Burrows P; Vogler H; Weinmann HJ Invest Radiol; 1996 Apr; 31(4):211-7. PubMed ID: 8721960 [TBL] [Abstract][Full Text] [Related]
9. A simple and inexpensive system for controlling body temperature in small animal experiments using MRI and the effect of body temperature on the hepatic kinetics of Gd-EOB-DTPA. Murase K; Assanai P; Takata H; Saito S; Nishiura M Magn Reson Imaging; 2013 Dec; 31(10):1744-51. PubMed ID: 24094686 [TBL] [Abstract][Full Text] [Related]
10. Gadolinium ethoxybenzyl diethylenetriamine pentaacetic acid-enhanced MR finding of radiation-induced hepatic injury: relationship to absorbed dose and time course after irradiation. Okamoto D; Nishie A; Asayama Y; Tajima T; Ishigami K; Kakihara D; Nakayama T; Ohga S; Yoshitake T; Shioyama Y; Honda H Magn Reson Imaging; 2014 Jul; 32(6):660-4. PubMed ID: 24666574 [TBL] [Abstract][Full Text] [Related]
12. Pharmacokinetics in rats, dogs and monkeys of a gadolinium chelate used as a liver-specific contrast agent for magnetic resonance imaging. Schuhmann-Giampieri G; Frenzel T; Schmitt-Willich H Arzneimittelforschung; 1993 Aug; 43(8):927-31. PubMed ID: 8216456 [TBL] [Abstract][Full Text] [Related]
13. Potential of gadolinium-ethoxybenzyl-diethylenetriamine pentaacetic acid (Gd-EOB-DTPA) for differential diagnosis of nonalcoholic steatohepatitis and fatty liver in rats using magnetic resonance imaging. Tsuda N; Okada M; Murakami T Invest Radiol; 2007 Apr; 42(4):242-7. PubMed ID: 17351431 [TBL] [Abstract][Full Text] [Related]
14. Phantom and animal studies of a new hepatobiliary agent for MR imaging: comparison of Gd-DTPA-DeA with Gd-EOB-DTPA. Yoshikawa K; Inoue Y; Akahane M; Shimada M; Itoh S; Seno A; Hayashi S J Magn Reson Imaging; 2003 Aug; 18(2):204-9. PubMed ID: 12884333 [TBL] [Abstract][Full Text] [Related]
15. Evaluation of gadoxetate disodium as a contrast agent for mouse liver imaging: comparison with gadobenate dimeglumine. Kiryu S; Inoue Y; Watanabe M; Izawa K; Shimada M; Tojo A; Yoshikawa K; Ohtomo K Magn Reson Imaging; 2009 Jan; 27(1):101-7. PubMed ID: 18599243 [TBL] [Abstract][Full Text] [Related]
17. New proposal for the staging of nonalcoholic steatohepatitis: evaluation of liver fibrosis on Gd-EOB-DTPA-enhanced MRI. Tsuda N; Okada M; Murakami T Eur J Radiol; 2010 Jan; 73(1):137-42. PubMed ID: 19026502 [TBL] [Abstract][Full Text] [Related]
18. A LC-MS/MS method to evaluate the hepatic uptake of the liver-specific magnetic resonance imaging contrast agent gadoxetate (Gd-EOB-DTPA) in vitro and in humans. Jia J; Keiser M; Nassif A; Siegmund W; Oswald S J Chromatogr B Analyt Technol Biomed Life Sci; 2012 Apr; 891-892():20-6. PubMed ID: 22391331 [TBL] [Abstract][Full Text] [Related]
19. Contrast-enhanced magnetic resonance cholangiography with Gd-BOPTA and Gd-EOB-DTPA in healthy subjects. Dahlström N; Persson A; Albiin N; Smedby O; Brismar TB Acta Radiol; 2007 May; 48(4):362-8. PubMed ID: 17453513 [TBL] [Abstract][Full Text] [Related]
20. Tissue gadolinium deposition in renally impaired rats exposed to different gadolinium-based MRI contrast agents: evaluation with inductively coupled plasma mass spectrometry (ICP-MS). Sato T; Ito K; Tamada T; Kanki A; Watanabe S; Nishimura H; Tanimoto D; Higashi H; Yamamoto A Magn Reson Imaging; 2013 Oct; 31(8):1412-7. PubMed ID: 23643157 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]